结构修饰以改进用于神经内分泌肿瘤的铅-203/铅-212 肽基影像引导 α 粒子放射性药物治疗
本研究设计并合成经修饰环化技术、引入铅特异性螯合剂(PSC)和聚乙二醇(PEG)连接子的 SSTR2 靶向肽,在 AR42J 肿瘤细胞和荷瘤小鼠模型中评估 203Pb 标记肽的结合、摄取、生物分布与显像,并进一步评估 212Pb 标记先导肽的治疗效果。先导放射性肽药物偶联物 [203Pb]Pb-PSC-PEG2-TOC 较 [203Pb]Pb-DOTATOC 显著改善肿瘤靶向性并加快肾脏清除;[212Pb]Pb-PSC-PEG2-TOC 呈剂量依赖性疗效且毒性迹象轻微,分次给药 3.7 MBq 三次使小鼠 120 天生存率达 80%(完全缓解 70%)。
要点
- PSC-PEG2-TOC 经修饰后较 DOTATOC 改善受体结合、肿瘤蓄积与滞留并加快肾脏清除。
- [212Pb]Pb-PSC-PEG2-TOC 在 AR42J 模型中呈剂量依赖性疗效且毒性迹象轻微。
- 分三次给予 3.7 MBq [212Pb]Pb-PSC-PEG2-TOC 使小鼠 120 天生存率达 80%(完全缓解 70%)。
核心结论
- 对螯合剂和连接子组成进行结构修饰可改善用于 NET 诊疗的 203/212Pb 肽基放射性药物的肿瘤靶向性和药代动力学(PK)。
- 这些发现提示 PSC-PEG2-TOC 是用于表达 SSTR2 的 NET 及其他类型癌症的铅基靶向放射性核素治疗的有前景候选物。
研究设计与样本
- 设计并合成经修饰环化技术、引入铅特异性螯合剂(PSC)和插入聚乙二醇(PEG)连接子的 SSTR2 靶向肽。
- 用胰腺 AR42J(SSTR2+)肿瘤细胞评估肽的结合亲和力及 203Pb 标记肽的细胞摄取。
- 在 AR42J 肿瘤异种移植小鼠模型中评估 203Pb 标记肽的生物分布和显像。
- 确定先导肽 PSC-PEG2-TOC 后进一步在 212Pb 治疗研究中评估疗效。
主要发现
- 先导放射性肽药物偶联物(RPDC)[203Pb]Pb-PSC-PEG2-TOC 较 [203Pb]Pb-DOTA0-Tyr3-奥曲肽(DOTATOC)显著改善受体结合、肿瘤蓄积和滞留等肿瘤靶向特性。
- 修饰后的 RPDC 较 DOTATOC 对应物表现出更快的肾脏清除。
- [212Pb]Pb-PSC-PEG2-TOC 的这些有利特性在 AR42J 异种移植模型中产生剂量依赖性治疗效果且毒性迹象轻微。
- 分次给予 3.7 MBq [212Pb]Pb-PSC-PEG2-TOC 共三次进一步改善抗肿瘤效果,使小鼠模型 120 天生存率达 80%(完全缓解 70%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The lead-203 (203Pb)/lead-212 (212Pb) elementally identical radionuclide pair has gained significant interest in the field of image-guided targeted alpha-particle therapy for cancer. Emerging evidence suggests that 212Pb-labeled peptide-based radiopharmaceuticals targeting somatostatin receptor subtype 2 (SSTR2) may provide improved effectiveness compared to beta-particle-based therapies for neuroendocrine tumors (NETs). This study aims to improve the performance of SSTR2-targeted radionuclide imaging and therapy through structural modifications to Tyr3-octreotide (TOC)-based radiopharmaceuticals. METHODS: New SSTR2-targeted peptides were designed and synthesized with the goal of optimizing the incorporation of Pb isotopes through the use of a modified cyclization technique; the introduction of a Pb-specific chelator (PSC); and the insertion of polyethylene glycol (PEG) linkers. The binding affinity of the peptides and the cellular uptake of 203Pb-labeled peptides were evaluated using pancreatic AR42J (SSTR2+) tumor cells and the biodistribution and imaging of the 203Pb-labeled peptides were assessed in an AR42J tumor xenograft mouse model. A lead peptide was identified (i.e., PSC-PEG2-TOC), which was then further evaluated for efficacy in 212Pb therapy studies. RESULTS: The lead radiopeptide drug conjugate (RPDC) - [203Pb]Pb-PSC-PEG2-TOC - significantly improved the tumor-targeting properties, including receptor binding and tumor accumulation and retention as compared to [203Pb]Pb-DOTA0-Tyr3-octreotide (DOTATOC). Additionally, the modified RPDC exhibited faster renal clearance than the DOTATOC counterpart. These advantageous characteristics of [212Pb]Pb-PSC-PEG2-TOC resulted in a dose-dependent therapeutic effect with minimal signs of toxicity in the AR42J xenograft model. Fractionated administrations of 3.7 MBq [212Pb]Pb-PSC-PEG2-TOC over three doses further improved anti-tumor effectiveness, resulting in 80% survival (70% complete response) over 120 days in the mouse model. CONCLUSION: Structural modifications to chelator and linker compositions improved tumor targeting and pharmacokinetics (PK) of 203/212Pb peptide-based radiopharmaceuticals for NET theranostics. These findings suggest that PSC-PEG2-TOC is a promising candidate for Pb-based targeted radionuclide therapy for NETs and other types of cancers that express SSTR2.
引用
- Lee D, Li M, Liu D, et al. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors. Eur J Nucl Med Mol Imaging. 2023. PMID: 37955792. doi:10.1007/s00259-023-06494-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。